Obstructive Sleep Apnea (OSA): When to Seek a Second Opinion

What Is OSA and How Is It Diagnosed?

Obstructive sleep apnea occurs when the upper airway collapses repeatedly during sleep, cutting off airflow for 10 seconds or longer. The American Academy of Sleep Medicine (AASM) defines OSA as an AHI of 5 or more per hour accompanied by symptoms such as excessive daytime sleepiness, witnessed apneas, or unexplained hypertension, or an AHI of 15 or more regardless of symptoms. [1]

The Role of Polysomnography vs. Home Sleep Testing

Full in-lab polysomnography (PSG) remains the gold-standard diagnostic test. Home sleep apnea testing (HSAT) is acceptable for patients with high pre-test probability and no significant comorbidities, but it tends to underestimate AHI because the device records only the time it is actively detecting breathing, not total sleep time. A 2020 Cochrane review found that HSAT had moderate sensitivity for ruling in moderate-to-severe OSA but missed a meaningful proportion of patients with mild disease. [2]

If you were diagnosed only by HSAT and your treatment is not working, requesting in-lab PSG is a reasonable first step toward a second opinion.

Understanding Your AHI Number

The AHI counts the total apnea and hypopnea events divided by hours of sleep:

| AHI Range | Severity | |---|---| | 5 to 14 | Mild | | 15 to 29 | Moderate | | >= 30 | Severe |

Oxygen desaturation index (ODI) and arousal index add clinical context that a single AHI number does not capture. Ask your provider for the full summary report, not just the final AHI.

Standard Treatment Options: What Guidelines Recommend

CPAP therapy is the first-line treatment for moderate-to-severe OSA and is supported by every major sleep guideline. The AASM strongly recommends positive airway pressure (PAP) as initial therapy, with the acknowledgment that adherence is a persistent clinical problem. [3]

CPAP: Effective When Used, Often Abandoned

CPAP eliminates apnea events in most patients when used correctly. The difficulty is sustained use. Studies consistently show that 46 to 83% of patients are non-adherent (defined as fewer than 4 hours per night on more than 70% of nights) at 12-month follow-up. [4]

Non-adherence matters clinically. A 2019 JAMA Internal Medicine analysis found that untreated moderate-to-severe OSA was associated with a hazard ratio of 2.6 for incident cardiovascular events compared with treated patients. [5]

If you are not using your CPAP at least 4 hours per night or you still feel unrefreshed after 90 days of consistent use, your current provider should be escalating to alternative or adjunctive therapies. Failure to do so is a signal to seek another evaluation.

Oral Appliance Therapy

Mandibular advancement devices (MADs) are a guideline-supported alternative for mild-to-moderate OSA and for patients who cannot tolerate CPAP. The AASM/American Academy of Dental Sleep Medicine joint clinical practice guideline recommends custom-fit MADs over over-the-counter devices because custom devices produce greater AHI reduction and better patient satisfaction. [6]

A real-world consideration: MADs reduce AHI by roughly 50% on average compared with 90% or more for CPAP, so they are not equivalent for severe disease.

Positional Therapy

Roughly 56% of OSA patients have positional OSA, defined as an AHI in the supine position at least twice the non-supine AHI. [7] Positional therapy devices (vibrotactile feedback worn on the chest or neck) represent an underused option that is rarely mentioned at routine follow-up appointments. If your provider has never asked about sleeping position, that is worth raising.

When Weight Loss Changes Everything

Obesity is present in approximately 60 to 90% of patients with moderate-to-severe OSA, and the relationship is bidirectional. Fat deposition narrows the upper airway, and OSA-related sleep fragmentation worsens insulin resistance and appetite dysregulation. [8]

Every 10 kg of weight loss reduces AHI by approximately 26% in patients with a BMI above 30 [9], though individual response varies substantially. Weight loss alone rarely cures severe OSA, but it meaningfully reduces CPAP pressure requirements and, in some patients, drops AHI below the treatment threshold entirely.

Tirzepatide (Zepbound) for OSA: The SURMOUNT-OSA Data

The FDA approved tirzepatide (Zepbound) in January 2024 specifically for moderate-to-severe OSA in adults with obesity. This was the first drug approval for OSA as a primary indication.

The SURMOUNT-OSA program consisted of two parallel randomized controlled trials (N=469 combined) published in the New England Journal of Medicine in 2024. In patients not using CPAP (Trial 1), tirzepatide 15 mg reduced mean AHI from 51.5 at baseline to 19.7 at 52 weeks, a 62.8% reduction. Placebo achieved a 6.4% reduction. Secondary endpoints including patient-reported sleepiness (Epworth Sleepiness Scale) and oxygen desaturation index also improved significantly (P<0.001 for all). [10]

In Trial 2, patients who remained on CPAP and added tirzepatide showed a 51.5% AHI reduction versus 13.6% for placebo plus CPAP.

These results mean that if you have moderate-to-severe OSA and a BMI at or above 30 and your clinician has not discussed tirzepatide, you have a concrete reason to seek another opinion.

GLP-1 Receptor Agonists: What the Data Shows Beyond Tirzepatide

Semaglutide (Ozempic, Wegovy) has not received an FDA indication for OSA, but trial data supports weight-loss-driven AHI improvement. The STEP-1 trial (N=1,961) showed a mean 14.9% body weight reduction at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo. [11] Body weight reduction of that magnitude would be expected to reduce AHI substantially in patients with obesity-related OSA, though direct AHI outcomes were not the primary endpoint of STEP-1.

A dedicated semaglutide OSA trial (SCALE Sleep Apnea, NCT04766177) reported results indicating clinically meaningful AHI reductions, though tirzepatide currently holds the only OSA-specific FDA label.

Surgical and Procedural Options

Surgery is appropriate when anatomical factors drive OSA and conservative measures have failed or are not tolerated. Multiple procedures exist, and the right choice depends on the specific site of obstruction.

Hypoglossal Nerve Stimulation (HNS)

Upper airway stimulation via an implanted hypoglossal nerve stimulator (brand name Inspire) is FDA-approved for adults with moderate-to-severe OSA (AHI 15 to 65) who have failed CPAP and have less than 25% central or mixed apneas on PSG. [12] The STAR trial (N=126) showed a 68% median reduction in AHI at 12 months, with 66% of patients achieving an AHI below 15. [13]

Inspire is significantly underutilized. If your AHI is between 15 and 65 and you cannot use CPAP, ask whether you have been evaluated for upper airway stimulation.

Soft Tissue and Skeletal Surgery

Uvulopalatopharyngoplasty (UPPP) is the most common soft tissue surgery but has highly variable outcomes, with success rates (defined as 50% AHI reduction and final AHI <20) ranging from 33% to 60% depending on patient selection. [14] Maxillomandibular advancement (MMA) surgery achieves AHI reductions comparable to CPAP in well-selected patients and is particularly effective for retrognathia.

These procedures require evaluation by an otolaryngologist or oral/maxillofacial surgeon with specific training in sleep surgery, not a general ENT. If you were offered UPPP without a drug-induced sleep endoscopy (DISE) to identify the specific collapse site, a surgical second opinion at an academic sleep center is warranted.

Red Flags That Signal You Need a Second Opinion

The following clinical framework identifies patients most likely to benefit from seeking additional evaluation. A second opinion should be considered if any single item applies.

Diagnostic red flags:

• You were diagnosed by HSAT alone and have persistent symptoms despite a normal or low-normal AHI result
• Your diagnostic study was performed more than 5 years ago and your weight has changed by more than 10 kg since then
• Your provider never discussed central vs. Obstructive events or never reviewed your oxygen desaturation index with you

Treatment red flags:

• You are using CPAP for 4 or more hours per night and still have an Epworth Sleepiness Scale score above 10
• Your titration pressure was set without an in-lab titration study or auto-titrating PAP (APAP) download review
• Oral appliances were dismissed without a trial or referral to a dentist trained in dental sleep medicine
• Your BMI is 30 or above and no clinician has discussed weight-loss pharmacotherapy including tirzepatide

Structural care-gap red flags:

• You have never been screened for hypothyroidism (TSH), acromegaly, or other secondary causes of OSA
• Cardiovascular risk (hypertension, atrial fibrillation, nocturnal dysrhythmias) has not been discussed in the context of your OSA severity
• You have never received a referral to an otolaryngologist or sleep surgeon despite two or more CPAP failures

OSA and Cardiovascular Risk: Why Undertreated OSA Is Not a Minor Problem

Moderate-to-severe untreated OSA is independently associated with hypertension, atrial fibrillation, heart failure, and stroke. The Sleep Heart Health Study (N=6,441) found that men in the highest quartile of AHI had an odds ratio of 1.42 for incident hypertension compared with those in the lowest quartile after adjusting for BMI, age, and smoking status. [15]

The AASM position statement notes: "OSA is a risk factor for cardiovascular disease, and treatment of OSA may reduce this risk." [16] This language is deliberately cautious because randomized trial data on hard cardiovascular endpoints for CPAP remains mixed. The ISAACC trial (N=2,717), published in the New England Journal of Medicine in 2022, found no significant difference in a composite cardiovascular endpoint between CPAP and usual care in patients with OSA and recent acute coronary syndrome over a median 3.4-year follow-up. [17]

This does not mean treatment is unimportant. The ISAACC population had low CPAP adherence (mean 2.8 hours per night), which almost certainly diluted the treatment signal. Adequate treatment, meaning 6 or more hours per night of CPAP or an equivalent alternative, remains the standard of care.

How to Prepare for a Second-Opinion Appointment

A productive second-opinion visit depends on what you bring, not just what the new provider orders.

Documents to Gather

Collect the following before your appointment:

1. Your original polysomnography or HSAT raw data report (not just the letter with your AHI)
2. CPAP or APAP device download showing nightly hours, residual AHI, leak data, and pressure history for the past 90 days
3. A completed Epworth Sleepiness Scale (available at sleepfoundation.org)
4. A list of current medications, since sedatives, opioids, muscle relaxants, and alcohol all worsen OSA
5. Recent weight and BMI, plus your weight 12 months ago if available

Questions to Ask the Consulting Provider

• "What is my primary collapse site and has drug-induced sleep endoscopy been considered?"
• "Am I a candidate for hypoglossal nerve stimulation given my AHI and anatomy?"
• "Would tirzepatide be appropriate for my OSA given my BMI?"
• "Has hypothyroidism been ruled out as a contributing factor?"

A sleep medicine fellowship-trained physician at an AASM-accredited center is the right specialist for a second opinion on complex or treatment-refractory OSA. Academic medical centers with dedicated sleep surgery programs are particularly well-equipped for cases where multiple interventions have failed.

OSA in Special Populations

Women and OSA Underdiagnosis

Women with OSA present less often with the classic triad of loud snoring, witnessed apneas, and obesity. They more commonly report insomnia, morning headache, and mood disturbance, which leads to misdiagnosis as depression or insomnia disorder. A 2019 study in the Journal of Clinical Sleep Medicine found that women waited an average of 4.5 years longer than men to receive an OSA diagnosis despite similar objective severity. [18]

If you are a woman whose insomnia or fatigue has not responded to standard treatments, requesting overnight PSG is appropriate even without witnessed snoring.

OSA After Menopause

Postmenopausal women have OSA prevalence rates approaching those of men of the same age, with estimates ranging from 47% to 67% in women aged 50 to 70. [19] Hormonal changes reduce upper airway muscle tone and alter ventilatory control. If you are postmenopausal and your sleep quality has declined significantly, OSA should be actively evaluated rather than attributed to menopause alone.

The Bottom Line on Getting a Second Opinion

Second opinions in sleep medicine are underused and underpromoted. The barriers are mostly psychological (feeling disloyal to a current provider) rather than logistical. Your AHI, oxygen desaturation data, and CPAP adherence metrics are objective numbers that a second set of clinical eyes can re-evaluate against current guidelines and emerging therapies.

The AASM 2022 clinical practice guideline for PAP therapy states that residual AHI above 5 events per hour on PAP therapy should prompt evaluation for mask leak, pressure inadequacy, positional factors, or coexisting central apnea before concluding that PAP has failed. [20] If your provider has not done that evaluation, you are entitled to find one who will.

In adults with moderate-to-severe OSA and obesity, the combination of optimized PAP therapy plus tirzepatide 15 mg achieved an AHI below 15 (the threshold for clinical significance) in 51.5% of patients at 52 weeks in SURMOUNT-OSA Trial 2, compared with 13.3% for PAP plus placebo. [10]